Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. by Marks, Michael et al.
1 
 
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study 1 
 2 
Michael Marks PhD, 1,2 Pere Millat-Martinez MD, 3 Dan Ouchi MSc, 4 Chrissy h. Roberts PhD, 1 Andrea 3 
Alemany BM, 5 Marc Corbacho-Monné BM, 5 Maria Ubals MD,6 Aurelio Tobias PhD 7, Cristian Tebé 4 
PhD8,9, Ester Ballana PhD4,6, Martí Vall-Mayans PhD,5,6 Camila G-Beiras PhD,5Nuria Prat MSc,6 Jordi 5 
Ara PhD,6 Bonaventura Clotet PhD,4,5,6,10 Oriol Mitjà PhD 5,6,9,10,11 6 
 7 
1. London School of Hygiene and Tropical Medicine, London, United Kingdom 8 
2. Hospital for Tropical Diseases, London, United Kingdom 9 
3. Barcelona Institute for Global Health – University of Barcelona, Barcelona, Spain 10 
4. IrsiCaixa AIDS Research Institute, Badalona, Spain 11 
5. Fight AIDS and Infectious Diseases Foundation, Badalona, Spain 12 
6. Hospital Universitari Germans Trias i Pujol, Badalona Spain 13 
7. Institute of Environmental Assessment and Water Research (IDAEA), Spanish Council for Scientific 14 
Research (CSIC), Barcelona, Spain 15 
 16 
8 Biostatistics Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL),  L'Hospitalet de 17 
Llobregat, Barcelona, Spain 18 
 19 
9. Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona , 20 
Barcelona, Spain. 21 
 22 
10. Universitat de Vic – Universtiat Central de Catalunya, Vic, Spain 23 
11. Lihir Medical Centre-InternationalSOS, Lihir Island, Papua New Guinea 24 
 25 
 26 
Corresponding author: Michael Marks 27 
Clinical Research Department,  28 
London School of Hygiene & Tropical Medicine 29 
London 30 
United Kingdom 31 
WC1E 7HT 32 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted December 23, 2020. ; https://doi.org/10.1101/2020.10.27.20220277doi: medRxiv preprint 





There remains limited data on what variables affect risk of transmission of SARS-CoV-2 and developing 35 
symptomatic Covid-19 and in particular the relationship to viral load (VL). We analysed data from linked 36 
index cases and their contacts to explore factors associated with transmission of SARS-CoV-2.  37 
Methods 38 
Patients were recruited as part of a randomized control trial ,conducted between March to April 2020, that 39 
aimed to assess if hydroxychloroquine reduced transmission of SARS-CoV-2. Non-hospitalised Covid-19 40 
cases and their contacts were identified through the local surveillance system. VL, measured by 41 
quantitative PCR from a nasopharyngeal swab, was assessed at enrollment, at day 14, and whenever the 42 
participant reported Covid-19-like symptoms. Risk of transmission, developing symptomatic disease and 43 
incubation dynamics were evaluated using regression analysis.  44 
Findings 45 
We identified 314 cases, 282 of which had at least one contact (753 contacts in total). Ninety (33%) of 46 
282 clusters had at least one transmission event. The secondary attack rate was 16% (125/753), with a 47 
variation from 12% to 24% for VL of the index case of <106, and >109 copies/mL, respectively (OR per  48 
log10 increase in VL 1.3 95%CI 1.1–1.6). Increased risk of transmission was also associated with 49 
household contact (OR 2.7; 1.4–5.06) and age of the contact (OR 1.02 per year; 1.01–1.04). The 50 
proportion of PCR positive contacts who developed symptomatic Covid-19 was 40.3% (181/449), with a 51 
variation from 25% to 60% for VL of the contact <107, and >109 copies/mL (HR log10 increase in VL 52 
1.12; 95% CI 1.05 – 1.2). Time to onset of symptomatic disease decreased from a median of 7 days (IQR 53 
5–10) for individuals with an initial viral load <107 to 6 days (4–8) and 5 days (3–8) for individuals with 54 
an initial viral load of 107–109 and >109, respectively.  55 
Interpretation 56 
Viral load of index cases is a leading driver of SARS-CoV-2 transmission. The risk of symptomatic 57 
Covid-19 is strongly associated with viral load of contacts at baseline and shortens the incubation time in 58 
a dose-dependent manner. 59 
 60 
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Funding: Crowdfunding campaign YoMeCorono (https://www.yomecorono.com/), and Generalitat de 61 
Catalunya. Support for laboratory equipment from Foundation Dormeur.  62 
 63 
Research in context 64 
Evidence before this study 65 
In September 2020, we searched PubMed database for articles reporting on factors influencing 66 
transmission and the risk of developing symptomatic disease. Search terms included “Covid-19”, “SARS-67 
CoV-2”, “transmission”, “incubation time”, and “risk”, with no language restrictions. By 20th September, 68 
various authors had reported on retrospective analyses of clusters of index cases and their corresponding 69 
contacts, as well as series of patients who developed symptomatic Covid-19 disease after PCR positive 70 
result. Besides describing the secondary attack rate, various authors identified risk factors for 71 
transmission associated with the place and duration of exposure and the lack of use of personal protective 72 
equipment. A single study suggested that symptomatic individuals might be more likely to transmit than 73 
asymptomatic cases but we found no clear evidence regarding the influence of viral load of the index case 74 
on transmission risk. Similarly, although various retrospective series of patients with positive PCR results 75 
had reported incubation times elsewhere, the characteristics of index case and contacts that may influence 76 
the risk of developing symptomatic Covid-19 and the time to this event had been barely addressed. 77 
Added value of this study 78 
We analyzed data from a large cluster-randomized clinical trial on post-exposure therapy for Covid-19 79 
that provide new information on SARS-CoV-2 transmission dynamics. Several design components add 80 
value to this dataset. Notably, quantitative PCR was available for the index cases to estimate risk of 81 
transmission. Furthermore, quantitative PCR was also performed on asymptomatic contacts at the time of 82 
enrollment allowing to investigate the dynamics of symptomatic disease onset among them. We found 83 
that the viral load of the index case was the leading determinant of the risk of SARS-CoV-2 PCR 84 
positivity among contacts. Among contacts who were SARS-CoV-2 PCR positive at baseline, viral load 85 
significantly influenced the risk of developing the symptomatic disease in a dose-dependent manner. This 86 
influence also became apparent in the incubation time, which shortened with increasing baseline viral 87 
loads. 88 
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Implication of all the available evidence 89 
Our results provide important insights into the knowledge regarding the risk of SARS-CoV-2 90 
transmission and Covid-19 development. The fact that the transmission risk is primarily driven by the 91 
viral load of index cases, more than other factors such as their symptoms or age, suggests that all cases 92 
should be considered potential transmitters irrespective of their presentation and encourages assessing 93 
viral load in cases with a larger number of close contacts. Similarly, our results regarding the risk and 94 
expected time to developing symptomatic Covid-19 encourage risk stratification of newly diagnosed 95 
SARS-CoV-2 infections based on the initial viral load. 96 
 97 
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According to current evidence, Covid-19 is primarily transmitted from person to person through 100 
respiratory droplets, as well as indirect contact, through transfer of the virus from contaminated fomites to 101 
the mouth, nose, or eyes.1,2 As with most respiratory viral infections there is likely to be some 102 
contribution from smaller aerosols but their relative contribution compared to droplets remains unclear. 103 
Several outbreak investigation reports have shown that Covid-19 transmission can be particularly 104 
effective in confined indoor spaces such as workplaces including factories, churches, restaurants, 105 
shopping centers, or healthcare settings.3–6 In Spain, and many other countries, healthcare workers have 106 
experienced a high rate of Covid-19 infection.7  107 
The availability of data regarding the factors that may enhance transmission is essential for designing 108 
interventions to control SARS-CoV-2 spread. Currently available data provide information on the risk of 109 
transmission related to the place and duration of exposure, and the use of respiratory and eye protection1,3–110 
5,8 but not on other factors related to the characteristics of index cases and their contacts. Over the course 111 
of infection, the virus has been identified in respiratory tract specimens 1–2 days before the onset of 112 
symptoms, and it can persist for prolonged periods over several weeks after the onset of symptoms in 113 
mild cases.9 However, the detection of viral RNA by PCR does not necessarily equate with infectivity, 114 
and the exact relationship between viral load and risk of transmission from a case is still not clear.10,11 115 
Studies investigating case-contact pairs have reported highly variable secondary attack rates (i.e., range 116 
0.7% to 75%), depending on the type of exposure―duration, place, pre- or post-symptomatic.12–15 117 
Another challenge for public health interventions is the risk stratification of infected individuals for 118 
developing symptomatic illness. On the other hand, a living systematic review estimated that the 119 
proportion of PCR-positive infected contacts that progress to symptomatic disease is approximately 70-120 
80%.16,17 Estimates of mean or median incubation period have been consistently between 5–7 days.18–20  121 
Whilst there has been a suggestion that viral load of cases may potentially be associated with risk of 122 
disease or transmission there is currently no published data directly addressing this question and little is 123 
known about factors that may contribute to variation on the risk of developing Covid-19 symptoms or the 124 
incubation periods among infected individuals.  125 
The overall aim of this study was to evaluate transmission dynamics of SARS-CoV-2 in the context of a 126 
trial of post-exposure prophylaxis. Specifically, the objectives of the study were threefold: (a) to 127 
investigate the association between clinical and demographic features of cases and viral load, (b) to 128 
evaluate the effect of viral load on SARS-CoV-2 transmission to close contacts, and (c) to determine the 129 
influence of viral load in the exposed on development of symptoms and on the incubation period. 130 
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Study design  132 
This was a post-hoc analysis of data collected in the BCN PEP CoV-2 Study (NCT04304053), a cluster-133 
randomized trial that included PCR-confirmed Covid-19 cases and their close contacts. The trial occurred 134 
between Mar 17 to Apr 28, 2020, during the SARS-CoV-2 outbreak, in three out of nine healthcare areas 135 
in Catalonia (North-East Spain): Catalunya central, Àmbit Metropolità Nord, and Barcelona Ciutat, total 136 
target population 4,206,440 people. The study protocol of the BCN PEP CoV-2 Study was approved by 137 
the ethics committee of Hospital Germans Trias Pujol, (Badalona, Spain). Written informed consent was 138 
obtained from all participants. Full details of the original study are reported elsewhere.21 139 
Covid-19 cases were identified using the electronic registry of the Epidemiological Surveillance 140 
Emergency Service of Catalonia (SUVEC) of the Department of Health.22 Following government 141 
ordinance, the SUVEC registered all new Covid-19 diagnoses occurred from March 16, 2020. The 142 
surveillance system included active tracing of all contacts with recent history of exposure, defined as 143 
being in contact with a SARS-CoV-2 PCR positive case during more than 15 minutes within two meters.  144 
All Covid-19 cases included in the present analysis were non-hospitalized adults (i.e., ≥ 18 years of age) 145 
with quantitative PCR result available at baseline, mild symptom onset within five days before 146 
enrollment, and no reported symptoms of SARS-CoV-2 infections in their accommodation (i.e., 147 
household or nursing home) or workplace within the 14 days before enrollment. Contacts selected for the 148 
analysis were adults with a recent history of exposure and absence of Covid-19-like symptoms within the 149 
seven days preceding enrolment. Contacts were exposed to the index case as either a healthcare worker, a 150 
household contact, a nursing home worker, or a nursing home resident. 151 
Study procedures and data collection 152 
A dedicated outbreak field team visited cases and contacts at home or nursing home on days 1 153 
(enrollment) and 14. At the first clinical assessment on day 1 they conducted a baseline assessment, 154 
including a questionnaire for symptoms of Covid-19 and collected relevant epidemiological information 155 
using a structured interview: time of first exposure to the index case, place of contact (hospital, home, 156 
nursing care facility), routine use of a mask of both when in close proximity to the index case, the case 157 
and the contact, and sleep location concerning the index case (e.g., same room, same house). Symptoms 158 
surveillance consisted of active monitoring by phone on days 3, and 7, a home visit on day 14, and 159 
passive monitoring whenever the participants developed symptoms. Participants who developed 160 
symptoms were visited the same day they notified symptom onset (unscheduled visits) by the field team, 161 
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which recorded the date of symptom onset, type of symptoms from a pre-specified checklist, and 162 
symptom severity, graded on a 1-to-4 scale. 163 
Serial SARS-CoV-2 PCR test and viral load titration on nasopharyngeal swab were conducted on day 1 164 
and day 14 to all participants, and on any unscheduled visit when the participant notified the onset of 165 
Covid-19 symptoms. The detection of the SARS-CoV-2 virus was performed from nasopharyngeal swabs 166 
at SYNLAB Diagnostics (Barcelona, Spain) by PCR using TaqMan™ 2019-nCoV Assay Kit according to 167 
the manufacturer’s protocol (Catalog number: A47532, Thermo Fischer Scientific Inc.). Viral load was 168 
quantified from nasopharyngeal swabs at IrsiCaixa laboratory (Badalona, Spain) by PCR amplification, 169 
based on the 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel guidelines and protocol 170 
developed by the American Center for Disease Control and Prevention (CDC).23 For absolute 171 
quantification, a standard curve was built using 1/5 serial dilutions of a SARS-CoV2 plasmid (2019-172 
nCoV_N_Positive Control, catalog no. 10006625, 2x105 copies/μL, Integrated DNA Technologies) and 173 
run in parallel to all PCR determinations. 174 
Outcomes and definitions 175 
Transmission was characterized by examining the number of infected and uninfected individuals among 176 
close contacts to an index case. We defined transmission events as PCR-positivity at any time point (i.e., 177 
days 1, 14, or at any other unscheduled PCR testing when participants referred symptoms) of a contact in 178 
the same household or workplace within the 14 days following enrollment. We defined the secondary 179 
attack rate of viral transmission as the ratio of PCR-positive individuals among close contacts, according 180 
to the WHO guidelines.  181 
Development to symptomatic disease was defined as presence of at least one of the following symptoms: 182 
fever, cough, difficulty breathing, myalgia, headache, sore throat, new olfactory and taste disorder(s), or 183 
diarrhea) and a positive SARS-CoV-2 RT-PCR test. The incubation period was defined as time from first 184 
exposure to symptom onset, with later confirmation of infection by PCR.24 The earliest possible exposure 185 
with the symptomatic index case was determined for each contact individually.  186 
Study Participants 187 
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We selected all eligible individuals within the original trial population for each of the three analyses 188 
conducted in the current study. As in the original trial there was no evidence of an impact of 189 
hydroxychloroquine on either transmission or development of symptomatic disease we included 190 
individuals in both arms of the trial in the current study. Firstly, all Covid-19 cases with quantitative PCR 191 
data were included in an analysis of the association between clinical and demographic features of cases 192 
and viral load. Secondly, we identified factors associated with transmission using all clusters of an index 193 
case (i.e., a Covid-19 case with at least one close contact) and their corresponding contacts for which 194 
quantitative viral load was available for the index case. Finally, we assessed the risk of developing 195 
symptomatic disease and the variation in the incubation period amongst all contacts with a positive PCR 196 
result at baseline, irrespective of available data of their index case.  197 
Statistical Analysis 198 
We used log transformed viral loads which were approximately normally distributed and which also align 199 
with common reporting norms. The relationship between characteristics of cases and viral load was 200 
assessed using linear regression considering age (in years), sex, the number of days from reported 201 
symptom onset and the presence of absence of five key clinical features namely fever, cough, shortness of 202 
breath or rhinitis and anosmia. To identify risk factors for transmission, we used logistic regression model 203 
for the risk of transmission utilizing a random-effect model to allow for within cluster variation in the risk 204 
of transmission. Factors with potential influence on the risk of transmission included characteristics of the 205 
potential transmitter (i.e., age, sex, viral load, and the presence or absence of respiratory symptoms) and 206 
contacts (i.e., age, sex, and the type of contact they had with the index case). Finally the risk of 207 
developing symptomatic Covid-19 was assessed by fitting a cox-regression model considering the age (in 208 
years) and sex of the individual, the presence or absence of cardiovascular disease, chronic respiratory 209 
disease and the initial viral load in relation to the time to development of symptomatic disease. Data at 14 210 
days after the first study visit were censored, in line with the follow-up conducted in the original trial. All 211 
analyses were conducted in R version 4.0.  212 
Role of the funding source 213 
The funder of the study had no role in the study design, data collection, data analysis, data interpretation, 214 
or writing of the report. All authors had full access to all the data in the study and had final responsibility 215 
for the decision to submit for publication. 216 
 217 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint 




Sample characteristics 219 
During the investigation period, we identified 314 cases in whom the viral load was tested. Overall, 220 220 
(70.0%) were female and the median age was 41 (IQR 31-52). Of them, 282 had at least one close 221 
contact, resulting in the corresponding clusters, with a total of 753 contacts. Clusters had a median of 2 222 
contacts (IQR 1-3) and a maximum of 19 contacts. Most index cases of the clusters were female (n= 202, 223 
71.6%), with an average age of 42 years (SD 13 years) (Table 1).  224 
Index case viral load 225 
The first study visit was performed a median of 4 days (IQR 3 -5) after symptom onset. At the first study 226 
visit, the mean viral load amongst Covid-19 cases was 108 (101.8). In multivariable linear regression the 227 
viral load amongst cases was higher in individuals who reported fever (Table 2) and negatively associated 228 
with the presence of anosmia but there was no association between the age or sex of the Covid-19 case 229 
nor the presence of reported dyspnea or cough. As anticipated viral load was negatively associated with 230 
the number of days since symptom onset.  231 
Cluster-level transmission 232 
For our risk factor analysis on SARS-CoV-2 transmission we used linked case and contact data of 282 233 
clusters with 753 contacts. At the cluster level, 90 (33.3%) of the 282 clusters had at least one 234 
transmission event, with a highly skewed distribution of the number of transmission events per cluster 235 
(Figure 1A). The first visit for contacts took place a median of 5 days (IQR 4-7 days) after their first 236 
possible exposure to the index case. A total of 125 (16.6%) of 753 contacts had a PCR positive result over 237 
the study period. The proportion of contacts who tested positive for SARS-CoV-2 within a cluster 238 
(secondary attack rate) progressively increased with the viral load of the index case: from 12% where the 239 
index case had a viral load of <106 copies/mL to 24% where the index case had a viral load >109 240 
copies/mL (Figure 1B). According to the multivariate analysis, the viral load of the index case was 241 
strongly associated with the risk of onward transmission (OR per log10 increase in VL 1.3; 95% CI 1.1-242 
1.6) (Table 3). Ninety percent (114/125) of transmission events had an index case viral load of 5.1 log10 243 
copies/ml or more, and 50% (61/125) had a viral load of 8.8 log10 copies/ml or more. Other factors 244 
associated with an increased risk of transmission were household contact (OR 2.7, 95% 1.4-5.06) and age 245 
of the contact (OR 1.02, 95% 1.01-1.04). There was no association of risk of transmission with reported 246 
mask usage by contacts, with the age or gender of the index case nor with the presence of respiratory 247 
symptoms in the index case at the initial study visit (Table 3).  248 
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We did not find any evidence of an association between the viral load of the index cases and the first viral 249 
load of incident positive results amongst contacts (p = 0.1, Supplementary Appendix) and this remained 250 
true when adjusting for both the day of illness on which the index cases baseline viral load was measured 251 
and the number of days until the contact was enrolled (p = 0.18). Also, after excluding contacts who were 252 
PCR positive at the first study visit, we found no association between the viral load of the index case and 253 
the time to onset of incident SARS-CoV-2 infection (HR 1.01 95% CI 0.83-1.23). 254 
Risk factor for Covid-19 disease among PCR+ contacts 255 
Overall, 449 contacts had a positive PCR result at first visit regardless of availability on viral load data of 256 
their index case (n=125) or not (n=324). Twenty-eight (6.3%) of 449 contacts had symptoms at the first 257 
visit and 181 (40.3%) developed symptomatic Covid-19 within the follow-up period. The multivariable 258 
cox-regression analysis, after adjusting for age and sex, revealed that increasing viral load levels of the 259 
contact at day 1 were associated with an increased risk of developing symptomatic disease. The risk of 260 
symptomatic disease was approximately 25% amongst individuals with an initial viral load of <107 261 
copies/mL compared to a more than 60% amongst those with an initial viral load of >109 (HR per log10 262 
increase in VL 1.12; 95% CI 1.05 – 1.2; p = 0.0006) (Figure 2A). In the multivariable analysis there was 263 
no association between sex or age of individuals nor the presence of diabetes, cardiovascular or 264 
respiratory disease and the risk or time to developing symptomatic Covid-19. 265 
The median time from exposure to symptom onset was 7 days (IQR 5 – 9). The time to onset of 266 
symptomatic disease decreased from a median of 7 days (IQR 5 – 10) for individuals with an initial viral 267 
load <107 copies/mL to 6 days (IQR 4 – 8) and 5 days (IQR 3 – 8) for individuals with an initial viral load 268 
of 107-109 and >109 copies/mL, respectively (Figure 2B).  Overall, 110/181 (60.8%) of participants who 269 
developed symptoms did so before day 8, 45/181 (24.9%) between days 8-10, and 22/181 (12.2%) 270 
between days 11-14.  271 
 272 
DISCUSSION 273 
In our study, we found that increasing viral load values in nasopharyngeal swabs of Covid-19 cases were 274 
associated with the greater risk of transmission measured by SARS-CoV-2 PCR positivity among 275 
contacts and also a higher risk of transmission in household environment compared to other indoor 276 
situations. In addition, we found that higher viral loads in swabs of asymptomatic contacts were 277 
associated with higher risk of developing symptomatic Covid-19 and have shorter incubation periods than 278 
those with a lower viral load.  Relationships between viral load and infectivity  have been described for 279 
other respiratory viruses and our study confirms the same is true for SARS-CoV-2.  280 
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To our knowledge this is the largest study that evaluates the relationship of viral load in Covid-19 cases 281 
and risk of transmission. In our cohort, a high proportion (67%) of index cases did not cause secondary 282 
infections. However, we identified 90 (33%) clusters with transmission events and the multivariate 283 
analysis revealed that clusters centered on index cases with high viral load were significantly more likely 284 
to result in transmission. Secondary attack rate was under 12% when the index case viral load was <106 285 
copies/ml compared to more than 20% amongst clusters with the highest viral loads. In line with previous 286 
analyses of case-contact clusters,9,12,14 we also found that household exposure to an index case was 287 
associated with a higher risk of transmission that other types of contact, presumably reflecting duration 288 
and proximity of exposure. Age of the contact was also identified in our multivariate analysis as a 289 
significant―albeit modest―determinant of transmission. This factor has shown uneven influence across 290 
results reported elsewhere, but seems to play a secondary role among adults.13,14 Finally, unlike previous 291 
analyses that reported a relationship between coughing and transmission,13 we did not find any 292 
association. This finding suggests that the absence of cough does not preclude significant onward 293 
transmission, particularly if the viral load is high. Taken together, our results indicate that the viral load, 294 
rather than symptoms, may be the predominant driver of transmission. 295 
Importantly, we report that high viral short after exposure in asymptomatic contacts was strongly 296 
associated with the risk of developing symptomatic Covid-19 disease. We found an approximately 25% 297 
chance of developing symptomatic disease amongst individuals with an initial viral load <107 copies/mL 298 
compared to a more than 60% chance amongst individuals with a viral load >109. These data may provide 299 
rationale for risk stratification for developing illness. Moreover, the initial viral load significantly shifted 300 
the incubation time, which ranged from 5 days in participants with a high viral load to 7 days in 301 
participants with a low viral load. Our study is the first analysis of prospective data that investigates the 302 
association between initial viral load and the incubation time.  303 
The study has several limitations. First, asymptomatic people were not enrolled as index cases, affecting 304 
our ability to fully characterize all types of transmission chain. Second, we did not find any evidence of 305 
decreased risk of transmission in individuals who reported mask use. While this finding collides with the 306 
evidence reported elsewhere,8 we did not have fine-grained data on type of mask (surgical vs FFP2), use 307 
of other measures of PPE or other infection control practices, thus limiting our ability to make clear 308 
inferences about the impact of PPE on transmission risk. Mask usage is likely correlated with type of 309 
exposure which might further confound associations but we did not note any association between mask 310 
use and risk either in our unadjusted analysis (Table 3) or in a multivariable model excluding type of 311 
exposure (data not shown). Third, we used time to symptom onset (with later confirmation of infection) 312 
rather than time to positive PCR test based on serial testing. Nonetheless, accurate calculation of the 313 
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incubation period was feasible because of the prospective nature of the study, accurate identification of 314 
exposure by face-to-face interview, and intensive active and passive monitoring of exposed contacts. We 315 
followed participants over 14-day periods, thus incubation periods beyond 14 days may not have been 316 
detected. Within each cluster we cannot be completely certain about the directionality of transmission, but 317 
our inclusion criteria including the absence of Covid-19 like symptoms in the 2 weeks proceeding 318 
enrolment is consistent with transmission from a case to a contact. We also cannot exclude that some 319 
individuals may have been infected by individuals outside of study clusters, but as per national guidelines 320 
all contacts were quarantined after exposure to index cases reducing the chance of transmission from 321 
elsewhere. Samples were available from index cases a median of four days after symptom onset and the 322 
initial sample in contacts was taken on average 5 days after exposure which may limit our ability to detect 323 
associations with peak viral load. Despite this we still demonstrate clear dose effects in relation to both 324 
risk of transmission and time to symptom onset. Finally, our study population is reflective of the trial 325 
from which the study sample is drawn and is therefore biased towards female participants, few 326 
comorbidities and predominantly mild-moderate infection and further data is needed on the risk of 327 
transmission in other populations. 328 
In summary, our results provide evidence regarding the determinants of SARS-CoV-2 transmission, 329 
particularly on the role of the viral load. The higher risk of transmission among individuals with higher 330 
viral loads adds to current evidence and encourages assessing viral load in cases with a larger number of 331 
close contacts. When a case with high viral load is identified, implementation of reinforced contact 332 
tracing measures and quarantines, may be critical to reduce onward transmission. Similarly, our results 333 
regarding the risk and expected time to developing symptomatic Covid-19 encourage risk stratification of 334 




MM, DO, OM accessed and verified the data. MM, DO, ChR, OM conceived of the study. MM 339 
performed the analysis. PM, AA, MCM, MU, MVM, CGB, NP, JA, BC, OM led the RCT from which 340 
study data is derived. MM and OM wrote the first draft of the manuscript. All authors gave critical input 341 
into interpretation and revised the manuscript.  342 
 343 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted December 23, 2020. ; https://doi.org/10.1101/2020.10.27.20220277doi: medRxiv preprint 
13 
 
CONFLICTS OF INTEREST 344 
We declare no conflicts of interest 345 
 346 
ACKNOWLEDGMENTS 347 
The authors would like to thank Gerard Carot-Sans for providing medical writing support during the 348 
preparation of the manuscript. 349 
REFERENCES 350 
1 La Rosa G, Bonadonna L, Lucentini L, Kenmoe S, Suffredini E. Coronavirus in water environments: 351 
Occurrence, persistence and concentration methods - A scoping review. Water Res 2020; 179: 115899. 352 
2 Umakanthan S, Sahu P, Ranade A V., et al. Origin, transmission, diagnosis and management of 353 
coronavirus disease 2019 (COVID-19). Postgrad Med J 2020; 0: 1–6. 354 
3 Leclerc QJ, Fuller NM, Knight LE, Funk S, Knight GM. What settings have been linked to SARS-355 
CoV-2 transmission clusters? Wellcome Open Res 2020; 5: 83. 356 
4 Qian H, Miao T, LIU L, Zheng X, Luo D, Li Y. Indoor transmission of SARS-CoV-2. medRxiv 2020; : 357 
2020.04.04.20053058. 358 
5 Hamner L, Dubbel P, Capron I, et al. High SARS-CoV-2 Attack Rate Following Exposure at a Choir 359 
Practice — Skagit County, Washington, March 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 606–360 
10. 361 
6 Park SY, Kim YM, Yi S, et al. Coronavirus disease outbreak in call center, South Korea. Emerg Infect 362 
Dis 2020; 26: 1666–70. 363 
7 Muñoz MA, López-Grau M. Lessons learned from the approach to the COVID-19 pandemic in urban 364 
primary health care centres in Barcelona, Spain. Eur J Gen Pract 2020; 26: 106–7. 365 
8 Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-366 
to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. The 367 
Lancet 2020; 395: 1973–87. 368 
9 Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their 369 
close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis 2020; 20: 911–9. 370 
10 Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with 371 
COVID-2019. Nature 2020; 581: 465–9. 372 
11 La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a 373 
management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin 374 
Microbiol Infect Dis 2020; 39: 1059–61. 375 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted December 23, 2020. ; https://doi.org/10.1101/2020.10.27.20220277doi: medRxiv preprint 
14 
 
12 Böhmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany 376 
resulting from a single travel-associated primary case: a case series. Lancet Infect Dis 2020; 20: 920–8. 377 
13 Wu J, Huang Y, Tu C, et al. Household Transmission of SARS-CoV-2, Zhuhai, China, 2020. Clin 378 
Infect Dis 2020; published online May 11. DOI:10.1093/cid/ciaa557. 379 
14 Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact Tracing Assessment of COVID-19 380 
Transmission Dynamics in Taiwan and Risk at Different Exposure Periods before and after Symptom 381 
Onset. JAMA Intern Med 2020; 180: 1156–63. 382 
15 Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID-19 during the 383 
incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside 384 
Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. J 385 
Infect 2020; 80: e1–13. 386 
16 Liu T, Gong D, Xiao J, et al. Cluster infections play important roles in the rapid evolution of COVID-387 
19 transmission: a systematic review. Int J Infect Dis 2020; 99: 374. 388 
17 Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of 389 
asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-390 
analysis. PLOS Med 2020; 17: e1003346. 391 
18 Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019- nCoV) 392 
infections among travellers from Wuhan, China, 20 28 January 2020. Eurosurveillance 2020; 25: 20–393 
8. 394 
19 Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-395 
infected pneumonia. N Engl J Med 2020; 382: 1199–207. 396 
20 Leung C. The difference in the incubation period of 2019 novel coronavirus (SARS-CoV-2) infection 397 
between travelers to Hubei and nontravelers: The need for a longer quarantine period. Infect Control 398 
Hosp Epidemiol 2020; 41: 594–6. 399 
21 Mitja O, Ubals M, Corbacho M, et al. A Cluster-Randomized Trial of Hydroxychloroquine as 400 
Prevention of Covid-19 Transmission and Disease. medRxiv 2020; : 2020.07.20.20157651. 401 
22 Catalan Ministry of Health. Catalan epidemiological surveillance system. 402 
http://salutpublica.gencat.cat/ca/ambits/vigilancia_salut_publica/ (accessed March 28, 2020). 403 
23 Centers for Disease Control and Prevention (CDC). CDC 2019-Novel Coronavirus (2019-nCoV) Real-404 
Time RT-PCR Diagnostic Panel. Cat. 2019-NCoVEUA-01. 2020. 405 
https://www.fda.gov/media/134922/download (accessed May 21, 2020). 406 
24 World Health Organization. The First Few X (FFX) Cases and contact investigation protocol for 2019-407 
novel coronavirus (2019-nCoV) infection, version 2. https://www.who.int/publications/i/item/the-first-408 
few-x-(ffx)-cases-and-contact-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-409 
infection (accessed Sept 21, 2020). 410 
  411 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint 




Table 1:  413 
Baseline Characteristics of linked transmission clusters 414 
Variable Value 
Cluster Size Median (IQR) 2 (1-3) 
Index Case Age Years – Mean (SD) 42 (13) 
Index Case Sex Female (%) 202 (64.%) 
Index Case Log Viral 
Load 
Mean (SD) 8 (1.8) 
Contacts Age  Years – Mean (SD) 42 (15) 
Contacts Gender Female (%) 385 (51.1%) 
 Male (%) 305 (40.5%) 
 Missing (%) 63 (8.4%) 
Baseline PCR of 
Contact Case 
Positive 93 (14.2%) 
Contact HCW 254 (33.7%) 
Household 382 (50.7%) 
Nursing Home 21 (2.8%) 
Unknown 96 (12.7%) 
 415 
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Table 2: Univariable and multivariable linear regression of association between Index case 417 
variables and log10 viral load 418 









Case Age N/A 0.002 (-0.02 – 0.02) 0.78 0.008 (-0.01 – 
0.02) 
0.38 
Case Sex Male 8.15  (7.54 – 8.77) Reference Reference 
Female 8.04 (7.47 – 8.6) -0.238 (-0.72 – 2.4) 0.33 -0.22 (-0.61 – 0.34) 0.59 
Days from Symptom 
Onset 
NA -0.17 (-0.26 – 0.0.8) 0.0002 -0.16 (-0.24 – 0.07) 0.0004 
Cough Absent 7.82 (7.24 – 8.41) Reference Reference 
Present 8.37 (7.78 – 8.95) 0.66 (0.22 – 1.1) 0.003 0.41 (-0.02 – 0.84) 0.06 
Dyspnea Absent  7.97 (7.5-8.43) Reference Reference 
 Present 8.22 (7.45-8.99( 0.27 (-0.40 – 0.94) 0.42 0.28 (-0.35 – 0.92) 0.38 
Fever Absent 7.77 (7.16 – 8.38) Reference Reference 
 Present 8.42 (7.86-8.98) 0.80 (0.36 – 1.24) 0.0004 0.43 (0.00 – 0.87) 0.05 
Anosmia Absent 8.32 (7.76 – 8.88) Reference Reference 
Present 7.87 (7.25-8.49) -0.57 (-1.0 - -0.09) 0.02 -0.54 (-1.0 – 0.09) 0.02 
Rhinits Absent 7.60 (7.23 – 7.98) Reference Reference 
Present 8.59 (7.65-9.52) 0.88 (-0.05 – 1.82) 0.06 0.77 (-0.11 – 1.66) 0.09 
 419 
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Index case age (per year) 1.02 0.99-1.05 0.07 1 0.99-1.03 0.46 
Female Index Case 0.74 0.4-1.36 0.33 0.71 0.37-1.39 0.32 
Index Case Viral Load 
(per Log10 change) 
1.27 1.09-1.48 <0.01 1.29 1.1-1.5 0.001 
Index Case Cough 1.0 0.55-1.82 0.99 1.13 0.64 – 2.0 0.66 
Index Case Dyspnea 0.80 0.31-2.07 0.64 0.75 0.30 – 1.89 0.55 
Index Case Rhinitis 1.46 0.46-4.63 0.52 1.31 0.42-4.11 0.64 
Age of Contact 1.03 1.01-1.05 <0.01 1.02 1.01 – 1.04 0.0008 
Female Contact 0.93 0.58-1.49 0.77 1.33 0.79 – 2.23 0.28 
Mask Use Never 1 
(Reference 
Group) 




Always 0.93 0.47 – 1.83 0.84 1.55 0.76 – 3.16 0.23 












Household 3.07 1.68-5.62 <0.01 3.0 1.59 – 5.65 0.0006 
Nursing 
Home  
1.75 0.19 -16.01 0.62 1.90 0.30 – 11.91 0.49 
Other 0.32 0.03-3.05 0.32 1.19 0.10 – 14.31 0.89 
 423 
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Figure 1: Transmission in a cluster 425 
 426 
(A) Number of secondary cases per cluster. (B) Relationship between viral load of the index case and the 427 
proportion of contacts developing Covid-19. Numbers 18/149 in group 104-105  RNA copies/ml; 30/2012 428 
in group 106-107; 59/298 in group 108-109; 17/71 in group ≥ 1010. 429 
 430 
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Figure 2. Risk of developing symptomatic Covid-19 according to characteristics of the contact at 432 
enrolment.  433 
 434 
(A) probability of symptomatic disease by viral load. (B) time to symptomatic disease by viral load. 435 
 436 
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Data Sharing Statement 438 
 439 
Marks M, Millat-Martinez P, Ouchi d et al. Transmission of Covid-19 in 282 clusters in 440 




Question Authors’ Response 
Will the data collected for your study 
be made available to others? 
Yes 
Which data? Complete de-identified patient data set 
   Will any supporting documents be 
   available? 
   Study protocol 
  
How or where can the data 
be obtained? 
mcorbacho@flsida.org 
When will data availability begin? 15/12/2020 
When will data availability end? 15/12/2021 
To whom will data be available? Researchers whose proposed use of the 
data has been approved 
For what type of analysis or 
purpose? 
For any purpose 
By what mechanism? By email 
Any other restrictions? — 
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